ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations

Journal Article · Sun Aug 15 04:00:00 EDT 2021 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2021.01.045· OSTI ID:23201016

McDuff, Susan G.R. ^[1]; Bellon, Jennifer R. ^[2]; Shannon, Kristen M. ^[3]; Gadd, Michele A. ^[4]; Dunn, Samantha ^[5]; Rosenstein, Barry S. ^[6]

---

1. Duke Cancer Center, Department of Radiation Oncology, Duke Cancer Center, Durham, North Carolina (United States)
2. Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Boston (United States)
3. Cancer Center Genetics Program, Massachusetts General Hospital, Boston (United States)
4. Department of Surgery, Massachusetts General Hospital, Boston (United States)
5. Department of Radiation Oncology, Massachusetts General Hospital, Boston (United States)
6. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York (United States)

Advances in germline genetic testing have led to a surge in identification of ataxia-telangiectasia mutated (ATM) variant carriers among breast cancer patients, raising numerous questions regarding use of breast radiation therapy (RT) in this population.

• OSTI ID: 23201016
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 110; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
GENETICS
MAMMARY GLANDS
NEOPLASMS
PATIENTS
RADIOTHERAPY
RECOMMENDATIONS